This Article Full Text Full Text (PDF) All Versions of this Article: 90/1/60    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager patientINFORMation Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sepilian, V. Articles by Nagamani, M. Search for Related Content PubMed PubMed Citation Articles by Sepilian, V. Articles by Nagamani, M. Related Collections Diabetes and Insulin Female Endocrinology

Effects of Rosiglitazone in Obese Women with Polycystic Ovary Syndrome and Severe Insulin Resistance

Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, University of Texas Medical Branch, Galveston, Texas 77555

Address all correspondence and requests for reprints to: Manubai Nagamani, M.D., Department of Obstetrics & Gynecology, University of Texas Medical Branch, Galveston, Texas 77555-0587. E-mail: mnagaman{at}utmb.edu.

Our objective was to evaluate the effectiveness of the insulin-sensitizing agent rosiglitazone in obese women with polycystic ovary syndrome (PCOS) and severe insulin resistance. Twelve obese women with PCOS were recruited. All were hirsute and anovulatory with acanthosis nigricans indicating severe insulin resistance. All women were treated with 4 mg of rosiglitazone daily for 6 months. A standard 75-g oral glucose tolerance test with insulin levels was performed before and after the women were treated with rosiglitazone. Glucose and insulin areas under the curve (AUC) were calculated. Serum levels of total and free testosterone, dehydroepiandrosterone sulfate, LH, and 17-hydroxyprogesterone were also measured before and after treatment. The body mass index was determined before and after treatment. There was a highly significant (r = 0.881, P < 0.0001) positive correlation between insulin response during oral glucose tolerance test and basal total testosterone levels. After treatment with rosiglitazone, there were significant decreases in fasting insulin levels (46.0 ± 6.5 vs. 16.9 ± 2.0 µU/ml; P < 0.001), insulin AUC (749.3 ± 136.3 vs. 225.0 ± 15.7 µU/ml; P = 0.003), fasting glucose levels (90.8 ± 3.0 vs. 81.8 ± 1.9 mg/dl; P = 0.003), and glucose AUC (437.9 ± 25.0 vs. 322.5 ± 14.7 mg/dl; P < 0.001). Both total testosterone (96.3 ± 17.3 vs. 56.1 ± 5.8 ng/dl; P = 0.01) and free testosterone (5.8 ± 0.6 vs. 3.4 ± 0.5 pg/ml; P < 0.001) decreased significantly after treatment, although there was no significant change in LH levels. Levels of SHBG increased significantly (18.3 ± 3.4 vs. 25.8 ± 6.6 nmol/liter; P = 0.009) after treatment, and dehydroepiandrosterone sulfate levels decreased significantly (P = 0.04). There was no significant change in body mass index (40.4 ± 2.4 vs. 41.1 ± 2.7 kg/m²). Eleven of the women reverted to regular ovulatory cycles during the treatment period. We conclude that 1) rosiglitazone therapy improves insulin resistance and glucose tolerance in obese women with PCOS; 2) rosiglitazone decreases ovarian androgen production, which appears to be independent of any changes in LH levels; 3) hyperinsulinemia appears to play a key role in the overproduction of ovarian androgens in these women because attenuation of insulin levels is associated with decreased testosterone levels; and 4) short-term rosiglitazone therapy helps restore spontaneous ovulation.

Find additional patient-related information at:

Rosiglitazone May Help Obese Women With Polycystic Ovary Syndrome

This article has been cited by other articles:

				M. Jensterle, A. Janez, B. Mlinar, J. Marc, J. Prezelj, and M. Pfeifer Impact of metformin and rosiglitazone treatment on glucose transporter 4 mRNA expression in women with polycystic ovary syndrome. Eur. J. Endocrinol., June 1, 2008; 158(6): 793 - 801. [Abstract] [Full Text] [PDF]

				D. Seto-Young, D. Avtanski, M. Strizhevsky, G. Parikh, P. Patel, J. Kaplun, K. Holcomb, Z. Rosenwaks, and L. Poretsky Interactions among Peroxisome Proliferator Activated Receptor-{gamma}, Insulin Signaling Pathways, and Steroidogenic Acute Regulatory Protein in Human Ovarian Cells J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 2232 - 2239. [Abstract] [Full Text] [PDF]

				P. Kempna, G. Hofer, P. E. Mullis, and C. E. Fluck Pioglitazone Inhibits Androgen Production in NCI-H295R Cells by Regulating Gene Expression of CYP17 and HSD3B2 Mol. Pharmacol., March 1, 2007; 71(3): 787 - 798. [Abstract] [Full Text] [PDF]

				R. Pasquali and A. Gambineri Insulin-sensitizing agents in polycystic ovary syndrome. Eur. J. Endocrinol., June 1, 2006; 154(6): 763 - 775. [Abstract] [Full Text] [PDF]

				K. Rautio, J.S. Tapanainen, A. Ruokonen, and L.C. Morin-Papunen Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study Hum. Reprod., June 1, 2006; 21(6): 1400 - 1407. [Abstract] [Full Text] [PDF]

				S. Chakrabarty, B. T. Miller, T. J. Collins, and M. Nagamani Ovarian Dysfunction in Peripubertal Hyperinsulinemia Reproductive Sciences, February 1, 2006; 13(2): 122 - 129. [Abstract] [PDF]

				N. A. Cataldo, F. Abbasi, T. L. McLaughlin, M. Basina, P. Y. Fechner, L. C. Giudice, and G. M. Reaven Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome Hum. Reprod., January 1, 2006; 21(1): 109 - 120. [Abstract] [Full Text] [PDF]

				A. Lemay, S. Dodin, L. Turcot, F. Dechene, and J-C. Forest Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance Hum. Reprod., January 1, 2006; 21(1): 121 - 128. [Abstract] [Full Text] [PDF]

				M. Yilmaz, N. Bukan, G. Ayvaz, A. Karakoc, F. Toruner, N. Cakir, and M. Arslan The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome Hum. Reprod., December 1, 2005; 20(12): 3333 - 3340. [Abstract] [Full Text] [PDF]

				D. Seto-Young, M. Paliou, J. Schlosser, D. Avtanski, A. Park, P. Patel, K. Holcomb, P. Chang, and L. Poretsky Direct Thiazolidinedione Action in the Human Ovary: Insulin-Independent and Insulin-Sensitizing Effects on Steroidogenesis and Insulin-Like Growth Factor Binding Protein-1 Production J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6099 - 6105. [Abstract] [Full Text] [PDF]

				S. Johnsen, S. E. Dolan, K. V. Fitch, K. M. Killilea, J. L. Shifren, and S. K. Grinspoon Absence of Polycystic Ovary Syndrome Features in Human Immunodeficiency Virus-Infected Women Despite Significant Hyperinsulinemia and Truncal Adiposity J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5596 - 5604. [Abstract] [Full Text] [PDF]

				I. Tarkun, B. Cetinarslan, E. Turemen, T. Sahin, Z. Canturk, and B. Komsuoglu Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome Eur. J. Endocrinol., July 1, 2005; 153(1): 115 - 121. [Abstract] [Full Text] [PDF]

				A. Vryonidou, A. Papatheodorou, A. Tavridou, T. Terzi, V. Loi, I.-A. Vatalas, N. Batakis, C. Phenekos, and A. Dionyssiou-Asteriou Association of Hyperandrogenemic and Metabolic Phenotype with Carotid Intima-Media Thickness in Young Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2740 - 2746. [Abstract] [Full Text] [PDF]